This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

The Severity-Weighted Assessment Tool (SWAT)

Seth R. Stevens, MD; Malcolm S. Ke, MD; Eileen J. Parry, MD; Julie Mark, MD; Kevin D. Cooper, MD

Arch Dermatol. 2002;138:42-48.

Objective  To develop a quantitative tool to assess severity of mycosis fungoides.

Design  Prospective analysis of a cohort.

Setting  University department of dermatology–based cutaneous lymphoma clinic.

Patients  From 1984 to 1995, 1186 visits from 323 referred patients seen in a multidisciplinary cutaneous lymphoma program.

Main Outcome Measures  Severity-weighted assessment tool (SWAT) scores were obtained for patients at each visit. This score represents the product of the percentage total body surface area (%TBSA) involvement of each lesion type (patch, plaque, and tumor or ulceration), multiplied by a weighting factor: SWAT = (patch %TBSA x 1) + (plaque %TBSA x 2) + (tumor or ulcer %TBSA x 3). In addition, the standard measurements of TBSA involvement and physician global assessments were recorded for comparison.

Results  The SWAT score correlated well with %TBSA (r = 0.95, P<.001), physician global assessment (r = 0.60, P<.001), and time to complete remission during psoralen–UV-A therapy (r = 0.80, P<.001), therefore indicating validity against standard measures. Analysis of individual and subsets of patients demonstrated that the SWAT score more accurately quantified changes in skin disease burden, including mixed responses to treatment, than did %TBSA alone.

Conclusions  The SWAT score is a useful clinical measurement for mycosis fungoides. The SWAT score captures overall physician impressions of disease status on a continuous dimensionless numerical scale, therefore providing a defined, objective, and sensitive quantitative measure. This tool is suitable for individual patient assessment, clinical trials, and outcome comparisons.

From the Departments of Dermatology, University Hospitals of Cleveland, Case Western Reserve University (Drs Stevens, Ke, Parry, Mark, and Cooper), and Veterans Affairs Medical Center (Drs Stevens and Cooper), Cleveland, Ohio; University of Michigan, Ann Arbor (Drs Stevens and Cooper); and Salford Royal Hospitals National Health Service Trust, Manchester, England (Dr Parry).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 2002;138(1):139.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prognostic Value of Blood Eosinophilia in Primary Cutaneous T-Cell Lymphomas
Tancrede-Bohin et al.
Arch Dermatol 2004;140:1057-1061.
ABSTRACT | FULL TEXT  

Circulating CD4+CD7- Lymphocyte Burden and Rapidity of Response: Predictors of Outcome in the Treatment of Sezary Syndrome and Erythrodermic Mycosis Fungoides With Extracorporeal Photopheresis
Stevens et al.
Arch Dermatol 2002;138:1347-1350.
ABSTRACT | FULL TEXT